ElectroHealing Technologies, Inc.
ElectroHealing Technologies, Inc. develops breakthrough improvements in medical technologies, and provides these solutions to unmet market needs to the multi-billion dollar market for medical solutions. ElectroHealing Technologies is the owner of multiple US Patents for innovations in medical devices, including US Patent 7,020,517, which covers deterring the onset of atrial and ventricular fibrillation using low voltage stimulation. The low cost circuit can be added to any pacemaker, defibrillator, or an add-on device. Atrial fibrillation deterrence has been demonstrated in animals in funded research. Ventricular fibrillation deterrence is in research.
Our management team has been involved in medical device innovation for many years and teamed with pacemaker inventor Wilson Greatbatch on the development of technologies to overcome the limitation of pacemakers and other implantable devices in safely working with MRI. After seven years of work the solutions to that problem were licensed to Boston Scientific and Guidant and the patent portfolio was sold to Medtronic in 2007. None of these patents were infringed at the time of these sales, and first MRI safe pacemaker actually shipped in August of 2011. Our team also created and co-managed a Collaborative Research and Development Agreement (CRADA) with the US FDA and generated research used to set the standard measurements for safety variables in implanted devices under MRI.
Our plan is to license our technology to manufacturers for a percentage of revenue. We do not plan to engage in device manufacturing or distribution. Our plan is to keep expenses low. There are many capabilities that will improve future medical devices. Our focus is enhanced algorithms and inventions that can greatly improve the functionality of implantable medical devices. This is an area with tremendous potential. Much of the innovation occurs with individual scientists, physicians and inventors. Our experience in product development, patenting, and government grants in support of early research and prototyping, opens new markets for innovations that may otherwise languish. It also provides a promising opportunity for a return on investment for our shareholders.